Literature DB >> 10699482

Contractile properties of human renal cell carcinoma recruited arteries and their response to nicotinamide.

M W Ruddock1, D M Burns, S R McKeown, L Murphy, I K Walsh, P F Keane, D G Hirst.   

Abstract

BACKGROUND AND
PURPOSE: The manipulation of tumour blood supply and thus oxygenation is a potentially important strategy for improving the treatment of solid tumours by radiation. Increased knowledge about the characteristics that distinguish the tumour vasculature from its normal counterparts may enable tumour blood flow to be more selectively modified. Nicotinamide (NA) causes relaxation of preconstricted normal and tumour-supply arteries in rats. It has also been shown to affect microregional blood flow in human tumours. Direct effects of NA on human tumour supply arteries have not previously been reported. This paper describes our evaluation of the effects of NA on two parameters: 'spontaneous', oscillatory contractile activity and agonist (phenylephrine)-induced constriction in the arteries supplying human renal cell carcinomas.
MATERIALS AND METHODS: Isolated renal cell carcinoma feeder vessels were perfused in an organ bath with the alpha(1)-adrenoceptor agonist phenylephrine (PE). When the arteries had reached a plateau of constriction, nicotinamide (8.2 mM) was added to the perfusate and changes in perfusion pressure were measured.
RESULTS: PE (10 microM) induced a sustained constriction in the majority of the renal cell carcinoma feeder vessels examined, demonstrating that they retain contractile characteristics, at least in response to this alpha(1)-adrenoceptor agonist. In combination with NA (8.2 mM) the constriction was significantly attenuated in half of the preparations. In addition, seven arteries exhibited spontaneous contractile activity which was significantly attenuated by NA in six of them.
CONCLUSIONS: NA can significantly attenuate both 'spontaneous' and agonist-induced constrictions in tumour-recruited human arteries, though not all arteries are sensitive.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699482     DOI: 10.1016/s0167-8140(99)00163-2

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

1.  N-Methyl-2-pyridone-5-carboxamide is 1-methylnicotinamide metabolite of low cyclooxygenase-dependent vasodilating activity.

Authors:  Tomasz Przygodzki; Bartlomiej Grobelski; Piotr Kazmierczak; Cezary Watala
Journal:  J Physiol Biochem       Date:  2012-01-13       Impact factor: 4.158

Review 2.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

3.  Vasomodulation of tumor blood flow: effect on perfusion and thermal ablation size.

Authors:  Hanping Wu; Agata A Exner; Tianyi M Krupka; Brent D Weinberg; John R Haaga
Journal:  Ann Biomed Eng       Date:  2008-12-16       Impact factor: 3.934

4.  Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

Authors:  Cian M McCrudden; Martin G O'Rourke; Kim E Cherry; Hiu-Fung Yuen; Declan O'Rourke; Muhammad Babur; Brian A Telfer; Huw D Thomas; Patrick Keane; Thiagarajan Nambirajan; Chris Hagan; Joe M O'Sullivan; Chris Shaw; Kaye J Williams; Nicola J Curtin; David G Hirst; Tracy Robson
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.